PMID- 35075092
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220226
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 92
IP  - 6
DP  - 2022 Jan 19
TI  - Do immunohistochemical studies have a role in predicting prognosis of laryngeal 
      squamous cell carcinomas? CD44 and Fascin experience.
PG  - e2021309
LID - 10.23750/abm.v92i6.10432 [doi]
LID - e2021309
AB  - BACKGROUND AND OBJECTIVES: The diagnosis of laryngeal squamous cell carcinoma 
      (LSCC) can be made easily based on histopathological findings, but the 
      relationship between morphological findings and prognosis is not clear. In 
      addition to morphological findings, the use of novel markers may contribute to 
      the development of new treatment strategies and improved patient prognosis. CD44, 
      which is a cancer stem cell marker, and Fascin-1, an actin-binding protein has 
      been associated with poor prognosis in many tumors. The aim of this study was to 
      investigate the relationship between CD44 and Fascin-1 expression and 
      clinicopathologic parameters in LSCC and their roles in the determination of 
      clinical behavior and prognosis. The aim of this study is to investigate whether 
      CD44 and Fascin have a relationship with clinicopathological parameters and have 
      a role in determining clinical behavior and prognosis in LSCC. METHODS: 130 
      patients who were operated in our hospital for LSCC between 2012 and 2018 were 
      included in this study. Fascin-1 and CD44 stains were applied 
      immunohistochemically to the paraffin blocks of the tumors. Immunostained 
      specimens were scored according to the intensity of staining and the percentage 
      of staining for each marker. Overall scores were summed and was designated as 
      immunoreactivity score (IRS). Finally, IRS was categorized into two groups; Low 
      and High CD44/Fascin IRS. RESULTS: There were no statistically significant 
      differences between low and high CD44 and Fascin IRS groups in terms of 
      clinicopathologic parameters, overall and disease-free survival (p> 0.05). 
      CONCLUSION: Immunhistochemical studies are not yet sufficient to predict patient 
      prognosis. Morphological findings still remain of priority and importance for 
      pathologists.
FAU - Ozturk, Cigdem
AU  - Ozturk C
AD  - Recep Tayyip Erdogan University Training and Research Hospital, Pathology 
      Department, Rize, Merkez, Rize, Turkey. dr.ozturkcigdem@gmail.com.
FAU - Pasaoglu, Husniye Esra
AU  - Pasaoglu HE
AD  - University of Health Science Bagcilar Training and Research Hospital, Pathology 
      Department. esrapasa2310@gmail.com.
FAU - Emre, Funda
AU  - Emre F
AD  - University of Health Science Bagcilar Training and Research Hospital, Pathology 
      Department. fkayaemre@yahoo.com.tr.
FAU - Tetikkurt, Umit Seza
AU  - Tetikkurt US
AD  - Demiroglu Bilim University Medical Faculty, Pathology Department. 
      umitseza@gmail.com.
FAU - Senturk Ege, Tulin
AU  - Senturk Ege T
AD  - University of Health Science Bagcilar Training and Research Hospital, 
      Otolaryngology Department. senturktulin@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220119
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - 0 (CD44 protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Microfilament Proteins)
RN  - 146808-54-0 (fascin)
SB  - IM
MH  - *Carcinoma, Squamous Cell/diagnosis
MH  - Carrier Proteins
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - Hyaluronan Receptors
MH  - Microfilament Proteins
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC8823588
COIS- Each author declares that he or she has no commercial associations (e.g. 
      consultancies, stock ownership, equity interest, patent/licensing arrangement 
      etc.) that might pose a conflict of interest in connection with the submitted 
      article.
EDAT- 2022/01/26 06:00
MHDA- 2022/01/28 06:00
PMCR- 2021/01/01
CRDT- 2022/01/25 05:48
PHST- 2020/08/10 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2022/01/25 05:48 [entrez]
PHST- 2022/01/26 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - ACTA-92-309 [pii]
AID - 10.23750/abm.v92i6.10432 [doi]
PST - epublish
SO  - Acta Biomed. 2022 Jan 19;92(6):e2021309. doi: 10.23750/abm.v92i6.10432.